Overview

Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts

Status:
Not yet recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

This is a single-arm, open-label, dose ramp-up exploratory clinical trial to evaluate the efficacy, safety and tolerance of aerosol inhalation of FB2001 as post-exposure prophylaxis among close contacts of COVID-19 patients. This study will enroll 20 to 60 close contacts of COVID-19 patients aging 18 to 65 years. After signing the informed consent form, the qualified subjects will be given FB2001 once or twice daily.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Ruijin Hospital

Collaborators:

Frontier Biotechnologies Inc.
Shanghai Center for Disease Control and Prevention